Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Renovis Gains Funding From Pfizer To Further VR1 Receptor Research

This article was originally published in The Pink Sheet Daily

Executive Summary

Extension of existing collaboration with Pfizer will fund Renovis’ research in the area through June 30, 2008.

You may also be interested in...



Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark

Eli Lilly is gaining a portfolio of molecules targeting the vanilloid-1 receptor, including Phase II candidate GRC 6211, through an agreement with Mumbai, India-based Glenmark Pharmaceuticals, announced Oct. 30

Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark

Portfolio includes Phase II candidate GRC 6211 for treatment of pain conditions, including osteoarthritic pain.

Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark

Portfolio includes Phase II candidate GRC 6211 for treatment of pain conditions, including osteoarthritic pain.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel